<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04742101</url>
  </required_header>
  <id_info>
    <org_study_id>CL1-65487-003</org_study_id>
    <secondary_id>2020-003061-19</secondary_id>
    <nct_id>NCT04742101</nct_id>
  </id_info>
  <brief_title>Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia</brief_title>
  <official_title>Phase I / II, Open Label, Dose Escalation Part (Phase I) Followed by Noncomparative Expansion Part (Phase II), Multi-centre Study, Evaluating Safety, Pharmacokinetics and Efficacy of S65487, a Bcl2 Inhibitor Combined With Azacitidine in Adult Patients With Previously Untreated Acute Myeloid Leukemia Not Eligible for Intensive Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ADIR, a Servier Group company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Servier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and clinical activity of the&#xD;
      combination S65487 with azacitidine in patients with acute myeloid leukaemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed in two parts: A single arm dose escalation phase I part and dose&#xD;
      expansion phase II part.&#xD;
&#xD;
      During dose escalation of S65487 in combination with azacitidine, only S65487 agent dose will&#xD;
      escalate and a DDI (Drug-Drug interaction) assessment between S65487 and posaconazole&#xD;
      (antifungal drug) will be performed.&#xD;
&#xD;
      For the expansion phase, Ramp up dose and full dose will be the RP2D (Recommended Phase 2&#xD;
      Dose) determined during phase I part&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT)</measure>
    <time_frame>From Ramp-up period (day 4 or day 3 before the first cycle) to the end of first cycle (each cycle is 28 days)</time_frame>
    <description>DLT assessment at the end of cycle 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>Through study completion, an average of 3 years ans 5 months</time_frame>
    <description>AE recording throughout the study evaluated according to CTCAE v5.0, dose interruptions, reductions, and intensity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PharmacoKinetics - maximum Concentration at the End of the infusion (Cinf)</measure>
    <time_frame>Cycle 1 (each cycle is 28 days) Day 1, Cycle 1 Day 8, Cycle 1 Day 15</time_frame>
    <description>PK parameters of S65487, azacitidine and potential metabolite(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PharmacoKinetics - Area Under the Curve (AUC)</measure>
    <time_frame>Ramp-up (day 4 or day 3 before the first cycle), Cycle 1(each cycle is 28 days) Day 1, Cycle 1 Day 8, Cycle 1 Day 9, Cycle 1 Day 15 and each Day 1 for following cycles</time_frame>
    <description>PK parameters of S65487, azacitidine and potential metabolite(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of anti-leukemic activity of S65487 combined to azacitidine</measure>
    <time_frame>Through study completion, an average of 3 years ans 5 months</time_frame>
    <description>Complete Response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of anti-leukemic activity of S65487 combined to azacitidine</measure>
    <time_frame>Through study completion, an average of 3 years and 5 months</time_frame>
    <description>Progression Free Survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>S65487 with azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S65487 and azacitidine</intervention_name>
    <description>Treatment cycle of combination of S65487 and azacitidine during 4 weeks. S65487 will be administered via intravenous (IV) infusion. Azacitidine will be administered via either subcutaneous (SC) or Intravenous (IV) infusion according to local practices.</description>
    <arm_group_label>S65487 with azacitidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female participant aged ≥ 18 years old&#xD;
&#xD;
          -  Participants with cytologically confirmed and documented treatment naïve, de novo or&#xD;
             secondary AML defined by WHO 2016 classification (Arber, 2016). Secondary AML&#xD;
             includes:&#xD;
&#xD;
               -  Previous myelodysplastic syndrome transformed&#xD;
&#xD;
               -  AML due to exposure to potentially leukemogenic therapies or agents (e.g.&#xD;
                  radiation therapy, alkylating agents, topoisomerase II inhibitors) with the&#xD;
                  primary malignancy in remission for at least 3 years&#xD;
&#xD;
          -  Participants not eligible for standard induction chemotherapy&#xD;
&#xD;
               -  Aged ≥ 75 years old&#xD;
&#xD;
               -  Or Age ≥18 years with at least one of the following comorbidities:&#xD;
&#xD;
                    -  Clinically significant heart or lung comorbidities, as reflected by at least&#xD;
                       one of:&#xD;
&#xD;
                         -  Lung diffusing capacity for carbon monoxide (DLCO) ≤65% of expected&#xD;
&#xD;
                         -  Forced expiratory volume in 1 second (FEV1) ≤65% of expected&#xD;
&#xD;
                    -  Other contraindication(s) to anthracycline therapy (must be documented)&#xD;
&#xD;
                    -  Other comorbidity that the Investigator judges as incompatible with&#xD;
                       intensive remission induction chemotherapy, which must be documented&#xD;
&#xD;
          -  ECOG (Eastern Cooperative Oncology Group) performance status should be (criterion&#xD;
             should be rechecked at inclusion visit) ECOG ≤ 2.&#xD;
&#xD;
          -  Written informed consent obtained prior any study-specific procedure as described in&#xD;
             section 13.3 of the protocol.&#xD;
&#xD;
          -  Adequate renal and hepatic function&#xD;
&#xD;
          -  Circulating White Blood Cell Count (WBC count) &lt; 25*109 G/L (with or without use of&#xD;
             hydroxycarbamide/leukapheresis)&#xD;
&#xD;
          -  Serum potassium, serum calcium, serum phosphates, serum magnesium within normal limits&#xD;
             with or without supplementation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major surgery within 3 weeks prior to the first IMP administration, or participants&#xD;
             who have not recovered from side effects of the surgery&#xD;
&#xD;
          -  Any radiotherapy within 3 weeks before the first IMP administration,&#xD;
&#xD;
          -  Allogenic stem cell transplant within 3 months before the first IMP administration&#xD;
             and/or participants with active Graft-versus-host disease within 3 months before the&#xD;
             first IMP administration and/or participants who still receive immunosuppressive&#xD;
             treatment within 3 months before the first IMP administration and/or participant who&#xD;
             receive donor lymphocyte infusion (DLI) within 3 months before the first IMP&#xD;
             administration&#xD;
&#xD;
          -  Acute promyelocytic leukemia (APL, French-American-British M3 classification)&#xD;
&#xD;
          -  Favorable risk cytogenetics such as t(8;21), inv(16) or t(16;16) or t(15;17) as per&#xD;
             the National Comprehensive Cancer Network (NCCN) Guidelines Version 2, 2016 for Acute&#xD;
             Myeloid Leukemia&#xD;
&#xD;
          -  Treatment with hypomethylating agents (decitabine/azacitidine) or Venetoclax for AHD&#xD;
             (antecedent hematologic disorders) in the 3 months prior to the first IMP intake&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital - Department of Hematology-Oncology</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center - Division of Hematology-Oncology</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre Servicio de Hematología</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>C. Universidad de Navarra Servicio de Hematologia</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Alfonso</last_name>
      <phone>0034 948 255 400</phone>
      <phone_ext>5801</phone_ext>
      <email>aalfonso@unav.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Universitario La Fe Servicio de Hematologia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College London - Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.servier.com/</url>
    <description>Find Results on Servier Clinical Trial Data website</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Dose escalation</keyword>
  <keyword>Phase I/II</keyword>
  <keyword>Azacitidine</keyword>
  <keyword>Combination</keyword>
  <keyword>Oncology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.&#xD;
Access can be requested for all interventional clinical studies:&#xD;
used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).&#xD;
where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.&#xD;
In addition, access can be requested for all interventional clinical studies in patients:&#xD;
sponsored by Servier&#xD;
with a first patient enrolled as of 1 January 2004 onwards&#xD;
for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After Marketing Authorisation in EEA or US if the study is used for the approval.</ipd_time_frame>
    <ipd_access_criteria>Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.</ipd_access_criteria>
    <ipd_url>https://clinicaltrials.servier.com/</ipd_url>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study-level clinical trial data</doc_type>
      <doc_url>https://clinicaltrials.servier.com/</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

